Company Overview and News
Because of my appreciation for the strength and stability of the five major Canadian banks, they as a group make up a significant portion of my Dividend Growth Investment (DGI) portfolio. I hold all five banks. But what sets them apart with respect to valuation? On analysis, I am of the view that Bank of Nova Scotia (Scotiabank) (NYSE:BNS) is the best buy today. I explore my reasons for this decision below.
BMO RY RY TNTTF BNS CM BMO TD TD BNS
Filed Pursuant to Rule 424(b)(2)
Submission Documents The information in this Preliminary Pricing Supplement is not complete and may be changed. We may not sell these notes until the Pricing Supplement is delivered in final f
Can't believe it has been this long since I made a stock purchase. The last purchase I made was AT&T (NYSE:T) back in June. It has been at least 4 months and my portfolio has been feeling a little neglected. But at least in all that time, it was still working hard for me and bringing in some quality dividends. I just recently surpassed my dividends collected for all of last year.
T BNS BNS
The information in this Pricing Supplement is not complete and may be changed
2018-10-13 seekingalpha - 1
Welcome back! September has historically been a slow month for dividend raises, and this year was no exception. The good news is that the fall is expected to see plenty of action. It all starts this week as there is one Canadian Dividend All-Star which is expected to announce its annual dividend raise. Before we get into that, there is plenty to catch up on from the past few weeks. Of note, all figures are in Canadian dollars unless otherwise noted.
TRI CWB BNS SIS FTS TRI SISXF FTS CBWBF BNS
Filed Pursuant to Rule 433 Registration
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to BNS / Bank of Nova Scotia (Halifax, NS) on message board site Silicon Investor.
|Bank of Nova Scotia Split||Bank of Nova Scotia Split||Bank of Nova Scotia Split|
as of ET